Drug Discovery

Baidu to integrate LinearDesign into Sanofi’s product design pipeline

Baidu, an AI company with internet foundation, has agreed to integrate its messenger ribonucleic acid (mRNA) design optimisation platform LinearDesign, into biopharmaceutical company Sanofi's product design pipeline.

Novo Nordisk to buy Dicerna to expand RNAi technology use

Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi technology use.

Pfizer acquires Trillium Therapeutics for $2.22bn

Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash.

Acelyrin raises $250m through Series B round

Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology.

AbbVie, University of Chicago extend oncology research collaboration

AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.

Regenxbio, AbbVie close license and collaboration deal to develop RGX-314

Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.

German, Austrian competition authorities approve Merck’s acquisition of Acceleron

Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.

Dunad, Novartis partner to develop oral protein degrader therapies

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.

Synthekine, Merck partner to develop new cytokine-based therapies

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics.